Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Tonkin

Showing results (41-50 of 163) with videos related to

Pageof 17
Sort By:
Clinical Trials (London, England)|November 26, 2008
Parametric conditional frailty models for recurrent cardiovascular events in the lipid studyJisheng Cui, Andrew Forbes, Adrienne Kirby, et al.
Heart (British Cardiac Society)|January 8, 2011
Discordant age and sex-specific trends in the incidence of a first coronary heart disease event in Western Australia from 1996 to 2007Tom Briffa, Lee Nedkoff, Anna Peeters, et al.
Australian and New Zealand Journal of Public Health|January 16, 2004
Accuracy of the Australian National Death Index: comparison with adjudicated fatal outcomes among Australian participants in the Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) studyDianna Magliano, Danny Liew, Helen Pater, et al.
BMC Medical Research Methodology|April 2, 2010
Semi-parametric risk prediction models for recurrent cardiovascular events in the LIPID studyJisheng Cui, Andrew Forbes, Adrienne Kirby, et al.
International Journal of Cardiology|January 21, 2010
Why did high-dose rosuvastatin not improve cardiac remodeling in chronic heart failure? Mechanistic insights from the UNIVERSE studyEmma Ashton, Emma Windebank, Marina Skiba, et al.
BMC Public Health|March 5, 2010
Absolute risk representation in cardiovascular disease prevention: comprehension and preferences of health care consumers and general practitioners involved in a focus group studySophie Hill, Janet Spink, Dominique Cadilhac, et al.
Heart Failure Reviews|July 29, 2016
The treatment gap in patients with chronic systolic heart failure: a systematic review of evidence-based prescribing in practiceKen Lee Chin, Marina Skiba, Andrew Tonkin, et al.
Diabetes Research and Clinical Practice|June 3, 2006
Association between impaired glucose metabolism and quality of life: results from the Australian diabetes obesity and lifestyle studyRobyn J Tapp, David W Dunstan, Pat Phillips, et al.
Journal of Cardiac Failure|March 7, 2007
Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failureHenry Krum, Emma Ashton, Christopher Reid, et al.
Environmental Science & Technology|September 8, 2011
Accumulation of microplastic on shorelines woldwide: sources and sinksMark Anthony Browne, Phillip Crump, Stewart J Niven, et al.
Pageof 17

Showing results (41-50 of 163) with videos related to

Sort By:
Pageof 17
Clinical Trials (London, England)|November 26, 2008
Parametric conditional frailty models for recurrent cardiovascular events in the lipid studyJisheng Cui, Andrew Forbes, Adrienne Kirby, et al.
Heart (British Cardiac Society)|January 8, 2011
Discordant age and sex-specific trends in the incidence of a first coronary heart disease event in Western Australia from 1996 to 2007Tom Briffa, Lee Nedkoff, Anna Peeters, et al.
Australian and New Zealand Journal of Public Health|January 16, 2004
Accuracy of the Australian National Death Index: comparison with adjudicated fatal outcomes among Australian participants in the Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) studyDianna Magliano, Danny Liew, Helen Pater, et al.
BMC Medical Research Methodology|April 2, 2010
Semi-parametric risk prediction models for recurrent cardiovascular events in the LIPID studyJisheng Cui, Andrew Forbes, Adrienne Kirby, et al.
International Journal of Cardiology|January 21, 2010
Why did high-dose rosuvastatin not improve cardiac remodeling in chronic heart failure? Mechanistic insights from the UNIVERSE studyEmma Ashton, Emma Windebank, Marina Skiba, et al.
BMC Public Health|March 5, 2010
Absolute risk representation in cardiovascular disease prevention: comprehension and preferences of health care consumers and general practitioners involved in a focus group studySophie Hill, Janet Spink, Dominique Cadilhac, et al.
Heart Failure Reviews|July 29, 2016
The treatment gap in patients with chronic systolic heart failure: a systematic review of evidence-based prescribing in practiceKen Lee Chin, Marina Skiba, Andrew Tonkin, et al.
Diabetes Research and Clinical Practice|June 3, 2006
Association between impaired glucose metabolism and quality of life: results from the Australian diabetes obesity and lifestyle studyRobyn J Tapp, David W Dunstan, Pat Phillips, et al.
Journal of Cardiac Failure|March 7, 2007
Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failureHenry Krum, Emma Ashton, Christopher Reid, et al.
Environmental Science & Technology|September 8, 2011
Accumulation of microplastic on shorelines woldwide: sources and sinksMark Anthony Browne, Phillip Crump, Stewart J Niven, et al.
Pageof 17